Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-2449 in Advanced Solid Tumors
NCT03917043Phase 1Recruiting
- Sponsor
- Ascentage Pharma
- Start
- May 2019
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of APG-2449 in solid tumor, non-small cell lung cancer (NSCLC), esophageal cancer and 2 more, sponsored by Ascentage Pharma. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase 2 dose at 28 days. Started May 2019; status: recruiting.
02
Drugs
APG-2449
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)esophageal cancerovarian cancermalignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT03917043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917043.